Ipsen S.A./€IPN
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Ipsen S.A.
Ipsen S.A. is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. The company focuses on the development and commercialization of innovative medicines in targeted therapeutic areas such as oncology, neuroscience, and rare diseases. Ipsen's key products include Somatuline, a treatment for neuroendocrine tumors and acromegaly, and Dysport, used for movement disorders and aesthetic indications. Founded in 1929 by Henri Beaufour, Ipsen has since expanded its presence worldwide, with a strategic emphasis on specialty care and the development of differentiated products. The company leverages its scientific expertise and research capabilities to sustain its competitive position in the biopharmaceutical industry.
Ticker
€IPN
Sector
Primary listing
PAR
Employees
5,358
Headquarters
Website
Ipsen S.A. Metrics
BasicAdvanced
€9.8B
22.17
€5.37
0.19
€1.40
1.18%
Price and volume
Market cap
€9.8B
Beta
0.19
52-week high
€123.92
52-week low
€86.78
Average daily volume
50K
Dividend rate
€1.40
Financial strength
Current ratio
1.984
Quick ratio
1.596
Long term debt to equity
19.811
Total debt to equity
20.237
Dividend payout ratio (TTM)
25.90%
Interest coverage (TTM)
36.76%
Profitability
EBITDA (TTM)
1,333
Gross margin (TTM)
83.32%
Net profit margin (TTM)
11.91%
Operating margin (TTM)
27.27%
Effective tax rate (TTM)
20.64%
Revenue per employee (TTM)
€700,000
Management effectiveness
Return on assets (TTM)
9.58%
Return on equity (TTM)
10.89%
Valuation
Price to earnings (TTM)
22.172
Price to revenue (TTM)
2.619
Price to book
2.33
Price to tangible book (TTM)
7.37
Price to free cash flow (TTM)
16.554
Free cash flow yield (TTM)
6.04%
Free cash flow per share (TTM)
7.195
Dividend yield (TTM)
1.18%
Forward dividend yield
1.18%
Growth
Revenue change (TTM)
9.45%
Earnings per share change (TTM)
-34.09%
3-year revenue growth (CAGR)
8.42%
10-year revenue growth (CAGR)
10.26%
3-year earnings per share growth (CAGR)
-15.39%
10-year earnings per share growth (CAGR)
12.24%
3-year dividend per share growth (CAGR)
5.27%
10-year dividend per share growth (CAGR)
5.12%
Bulls say / Bears say
H1 2025 sales increased 11.4% at constant exchange rates, and Ipsen raised its FY 2025 targets to more than 7% sales growth and over 32% core operating margin, with management showing strong confidence in future growth.
Ipsen’s Rare Disease portfolio saw 95.7% sales growth at constant exchange rates in H1 2025, underscoring rapid expansion in high-value specialty care markets.
A share buyback program for up to 600,000 shares highlights Ipsen's balance sheet strength and management's commitment to increasing shareholder value.
Ipsen shares dropped over 6% despite raising full-year guidance, as strong Somatuline results were outweighed by disappointment in the broader portfolio and concerns about the quality of sales.
Full-year guidance reflects an expected negative impact from greater generic competition on Somatuline in the U.S. and Europe, pointing to risks for key revenue streams.
The upcoming pivotal Phase IIb FALKON trial results for fidrisertib in fibrodysplasia ossificans progressiva represent a high-stakes event; negative data could significantly hurt valuation.
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ipsen S.A. stock?
Ipsen S.A. (IPN) has a market cap of €9.8B as of September 16, 2025.
What is the P/E ratio for Ipsen S.A. stock?
The price to earnings (P/E) ratio for Ipsen S.A. (IPN) stock is 22.17 as of September 16, 2025.
Does Ipsen S.A. stock pay dividends?
Yes, the Ipsen S.A. (IPN) stock pays dividends to shareholders. As of September 16, 2025, the dividend rate is €1.4 and the yield is 1.18%. Ipsen S.A. has a payout ratio of 25.9% on a trailing twelve-month basis.
When is the next Ipsen S.A. dividend payment date?
The next Ipsen S.A. (IPN) dividend payment date is unconfirmed.
What is the beta indicator for Ipsen S.A.?
Ipsen S.A. (IPN) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.